Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reduced blood EPAC1 protein levels as a marker of severe Coronary Artery Disease: The role of hypoxic foam cell-transformed smooth muscle cells

  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Polishuck, Anna
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Piñero, Janet|||0000-0003-1244-7654
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Leta, Rubén|||0000-0003-4691-381X
  • Viladés Medel, David|||0000-0002-3638-9703
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Vascular smooth muscle cells loaded with cholesterol (foam-VSMCs) play a crucial role in the progression of human atherosclerosis. Exchange Protein Directly Activated by cAMP 1 (EPAC1) is a critical protein in the regulation of vascular tone, endothelial function, and inflammation. Our objectives were to identify proteins specifically secreted by foam human coronary VSMCs (foam-hcVSMC) to evaluate their potential as circulating biomarkers for diagnosing coronary artery disease (CAD), and to ascertain the mechanisms underlying their levels in the blood of patients with CAD. Methods and Results: Differential proteomics identified EPAC1 as a differential foamhcVSMC-secreted protein. Circulating EPAC1 levels were measured by ELISA in blood from 202 patients with suspected CAD who underwent coronary computed tomography angiography (CCTA). Blood EPAC1 levels were significantly lower in CAD patients compared to controls (p < 0.001). EPAC1 levels were reduced in both men and women with severe CAD (SIS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of school SES on literacy development

  • Salas, Naymé|||0000-0002-5535-6069
  • Pascual, Mariona|||0000-0002-2985-235X
Effective literacy skills are essential to actively participate in today's society. However, little research has been conducted that examined the impact of contextual variables on literacy development. The present paper addressed whether and how the socioeconomic status of the school (S-SES) children attend affects their literacy achievements. Eight-hundred and seventy-eight 2nd and 4th grade children participated in the study. Data were collected in low-SES (vulnerable) and in mid-high-SES (non-vulnerable) schools. Children completed a large battery of language, cognitive, and literacy tasks in Catalan, a language spoken in a region in Spain where virtually all children are at least bilingual (they also speak Spanish) and it is the main language of instruction. Results showed that children in vulnerable schools were outperformed by children in non-vulnerable schools across all literacy competencies, but particularly affected higher order skills; that is, text quality and reading comprehension. Differences with their non-vulnerable peers remained, even after controlling for context-level covariates, including familial SES. However, S-SES ceased to exert significant influence once children's cognitive and, especially, linguistic skills were considered. The study adds to previous research claiming that school SES has an effect on students' literacy skills, above and beyond children's home SES. However, our findings also suggest that literacy performance is ultimately mostly dependent on educationally actionable, subject-level skills. Educational implications are discussed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early-Stage Breast Cancer Detection in Breast Milk

  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ortiz, Carolina|||0000-0002-5523-829X
  • Matito, Judit|||0000-0001-7560-7737
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Suñol Camas, Anna
  • Martín, Ágatha|||0000-0003-4818-6433
  • Cordoba Cardona, Octavi|||0000-0002-9591-7430
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Miranda, Ignacio|||0000-0002-4813-5946
  • Morales-Comas, Clara|||0000-0001-6771-6749
  • Carrasco, Estela|||0000-0003-1964-7675
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Peg, Vicente|||0000-0002-5203-6166
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bayó-Puxan, Neus|||0000-0001-9909-1499
  • González Medina, Alberto, 1990-|||0000-0002-2819-9053
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Arévalo, Silvia|||0000-0001-8169-1322
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Tabernero, Josep|||0000-0002-2495-8139
  • Vivancos, Ana|||0000-0003-2888-6512
  • Sansó, Miriam|||0000-0001-7155-4041
The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis. For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Written corrective feedback at university, Detection of errors by teachers and impact of different forms of feedback

  • Birello, Marilisa|||0000-0002-3744-7645
  • Comajoan-Colomé, Llorenç|||0000-0001-9815-6748
  • Salguero Garcia, Tania|||0009-0000-8678-5491
  • Sorolla, Natxo|||0000-0001-7480-0359
This study explores the written corrective feedback provided by two university teachers in the academic texts written by their students. Specifically, it focuses on the relationship established between the linguistic and discursive errors identified by the teachers, the forms of feedback provided (direct, indirect, metalinguistic and metadiscursive) and the impact of feedback on a second version of the texts revised by the students. A total of 142 texts (two versions of 71 texts) submitted by two groups of students taking a primary education degree at two Spanish universities (71 students) were analyzed. These were coded according to the errors detected, the form of feedback provided, and the way in which they incorporated the feedback into a second version. The results show that the errors detected in the highest numbers by the teachers were discursive, followed by morpho-syntactic and spelling mistakes. The most common feedback was indirect, followed by metalinguistic, although the two teachers were found to take distinct approaches. Regarding its impact, the students incorporated a high percentage (80%) of the feedback provided., Cette étude explore la rétroaction corrective écrite fournie par deux professeurs d'université dans des textes académiques rédigés par leurs étudiants. Plus précisément, elle se concentre sur la relation établie entre les erreurs linguistiques et discursives identifiées par les enseignants, les formes de rétroaction fournies (directes, indirectes, métalinguistiques et métadiscursives) et l'impact de la rétroaction sur une deuxième version des textes révisés par les étudiants. Au total, 142 textes (deux versions de 71 textes) soumis par deux groupes d'étudiants suivant un programme d'enseignement primaire dans deux universités espagnoles (71 étudiants) ont été analysés. Ils ont été codés en fonction des erreurs détectées, de la forme de rétroaction fournie et de la manière dont les étudiants ont incorporé la rétroaction dans une deuxième version. Les résultats montrent que les erreurs détectées en plus grand nombre par les enseignants sont les erreurs discursives, suivies des erreurs morphosyntaxiques et orthographiques. La forme de rétroaction la plus fréquente était indirecte, suivie par la rétroaction métalinguistique, bien que les deux enseignants aient adopté des approches distinctes. En ce qui concerne l'impact, les étudiants ont intégré un pourcentage élevé (80 %) de la rétroaction fournie.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Metodología para la Obtención de Modelos Semifísicos de Base Fenomenológica Aplicada a una Sulfitadora de Jugo de Caña de Azúcar, Methodology for Obtaining Phenomenological Based Semiphysical Models applied to a Sugar Cane Sulphitation Tower

  • Alvarez, Hernán
  • Lamanna, Rosalba
  • Vega Cruz, Pastora
  • Revollar, Silvana
[ES] En este trabajo se presentan los Modelos Semifísicos de Base Fenomenológica (MSBF) como herramienta útil en el diseño, control y optimización de procesos químicos y biotecnológicos. Se realiza una descripción detallada de un método para la obtención de MSBF a partir del conocimiento y principios básicos de los procesos: balances de materia, energía y cantidad de movimiento, así como el principio de gradiente para ecuaciones constitutivas. Se aplica el procedimiento descrito a la etapa de clarificación de un ingenio azucarero. En particular, se modela la torre de sulfitación de dicha etapa. El modelo se contrasta con el comportamiento de una sulfitadora real a través de simulación., [EN] This work presents the Phenomenological Based Semi-physical Model (PBSM) as a useful tool for the design, control and optimization of chemical and bio-technology processes. First, a detailed description of a methodology to obtain a PBSM based on the knowledge of the basic principles of the process: mass, energy and momentum conservation, as well as gradient principle for obtaining model constitutive equations. The described methodology is applied to the clarification stage of a sugar cane refining plant. Specifically, the sulfitation tower is modelled step by step. The model is simulated and validated by comparing its behaviour with data taken from a real sulfitation tower., CYTED (506RT0303). MCYT (DPI2006-15716-C02-01) y Decanato de Investigación y Desarrollo de la Universidad Simón Bolívar (Venezuela)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A versatile drug delivery system targeting senescent cells

  • Muñoz-Espín, Daniel
  • Rovira, M.
  • Galiana, Irene
  • Giménez Morales, Cristina
  • Lozano-Torres, Beatriz
  • Páez Ribes, M.
  • LLanos, Susana
  • Chaib, Selim
  • Muñoz-Martín, M.
  • Ucero, Alvaro C.
  • Garaulet, G.
  • Mulero, F.
  • Dann, S.G.
  • VanArsdale, T.
  • Shields, D.J.
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Murguía, Jose R.|||0000-0001-9364-4603
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Senescent cells accumulate in multiple aging-associated diseases, and eliminating these cells has recently emerged as a promising therapeutic approach. Here, we take advantage of the high lysosomal beta-galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto-oligosaccharides. We show that gal-encapsulated fluorophores are preferentially released within senescent cells in mice. In a model of chemotherapy-induced senescence, gal-encapsulated cytotoxic drugs target senescent tumor cells and improve tumor xenograft regression in combination with palbociclib. Moreover, in a model of pulmonary fibrosis in mice, gal-encapsulated cytotoxics target senescent cells, reducing collagen deposition and restoring pulmonary function. Finally, gal-encapsulation reduces the toxic side effects of the cytotoxic drugs. Drug delivery into senescent cells opens new diagnostic and therapeutic applications for senescence-associated disorders., We are grateful to D. Megias, L. Martinez, O. Dominguez, F. Al-Shahrour, C. Fustero, O. Graria, G. Garnez-Lapez, A. De Martino, P. Gonzalez, M. Udriste for technical support. Work in the laboratory of R.M.-M was funded by Projects MAT2015-64139-C4-1-R, PROMETE011/2014/047, and by Institute de Salud Carlos III through the project "DTS16/00205" (Co-funded by European Regional Development Fund/European Social Fund "Investing in your future"). Work in the laboratory of M.S. was funded by the CNIO and the IRB, and by grants from the Spanish Ministry of Economy (MINECO, SAF), the European Research Council (ERC Advanced Grant), the Botin Foundation and Banco Santander (Santander Universities Global Division), and by "la Caixa" Foundation. CNIO and IRB Barcelona are recipients of a Severo Ochoa Award of Excellence from the MINECO. D.M.-E was holder of a "Ramon y Cajal" Programme Senior Grant (MINECO, RYC-2013-14471) and was funded by a National Programme for Research Aimed at the Challenges of Society (MINECO, BFU2014-60020-R). Work in the laboratory of D.M.-E. was funded by Cancer Research UK (CRUK, C9685/A25177), and by the CRUK Cambridge Centre Early Detection Programme (RG86786). M.R. was holder of a "la Caixa"-Severo Ochoa PhD scholarship. I.G., B.L.-T., and A.B. were funded by the Generalitat Valenciana and the MINECO. Part of this work has been funded by a research collaboration agreement between Pfizer Inc. and the laboratories of RM.-M. and M.S. The fenders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Diseño Simultáneo de Proceso y Control de una Torre Sulfitadora de Jugo de Caña de Azúcar, Simultaneous Design and Control of a Sugar Cane Sulfitation Tower

  • Lamanna, Rosalba
  • Vega, Pastora
  • Revollar, Silvana
  • Álvarez, Hernán
[ES] Este trabajo se aborda el problema de diseño y control de una planta perteneciente a una etapa clave del proceso de obtención del azúcar de caña como es la clarificación. Se presenta una aproximación novedosa al problema de diseño y control simultáneo del proceso considerando tanto la controlabilidad de estado (basada en métricas de controlabilidad práctica) como la controlabilidad de salida (basada en índices dinámicos de control), tomando como ejemplo el caso de la torre sulfitadora. Esta propuesta se traduce en un problema de optimización no lineal donde se imponen restricciones sobre las condiciones de operación de la planta, las medidas de controlabilidad de estado y algunos índices de desempeño a lazo cerrado, mientras se minimizan los costos de inversión, operación y control. El problema de optimización se resolvió satisfactoriamente empleando algoritmos genéticos., [EN] This work focuses in the design and control of a plant used in the clarification stage of the sugar cane juice refining process. An innovative approach to the simultaneous design and control problem is presented, which considers the state controllability (based on practical controllability metrics) and the output controllability (based on dynamical performance indices) using as example the sulphitation tower. This statement translates into a non linear optimization problem where constraints are imposed over the plant operating conditions, the state controllability metrics and some closed loop performance indices while the investment, operating and control costs are minimized. The optimization problem was solved successfully using genetic algorithms., Los autores agradecen el apoyo de la Red de Automatización y Control de la Industria de Transformación de la Caña de Azúcar. Red temática CYTED (506RT0303). Área temática de tecnologías para la información y comunicaciones. El proyecto DPI2006-15716-C02-01 del MCYT (España) y el proyecto DI-CAI-002-05 del Decanato de Investigación y Desarrollo de la Universidad Simón Bolívar ( DICAI-002-05)
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Fungistatic and fungicidal capacity of a biosurfactant extract obtained from corn steep water

  • Lopez Prieto, Alejandro
  • Vecino Bello, Xanel
  • Rodríguez López, Lorena
  • Moldes Menduiña, Ana Belén
  • Cruz Freire, José Manuel
Biosurfactants are surface-active compounds that are produced by microorganisms, which in addition to their surfactant capacity, can possess interesting antimicrobial activities that are used in their incorporation into the agrifood industry. In this work, the preservative capacity of a novel biosurfactant extract obtained from a residual stream of the corn-milling industry was evaluated against two different fungi (Aspergillus brasiliensis and Candida albicans) under different biosurfactant concentrations (0.33–0.99 mg/mL), temperatures (4–40 °C), and incubation times (5–11 days). All the assays started with the same concentration of fungi (2 × 106 CFU/mL). The results showed that temperature played an important role in the fungicidal and fungistatic effects of this biosurfactant extract. It was observed that at a low biosurfactant concentration (0.33 mg/mL) and at low temperatures in the range tested, this biosurfactant extract possessed an important fungicidal effect (complete inhibition) on A. brasiliensis, while at intermediate temperatures, it achieved a fungistatic effect (50% of inhibition) at the highest concentration. Regarding C. albicans, it was observed that this strain was more resistant than A. brasiliens, although it was possible to achieve growth inhibitions of 76.3% at temperatures of 40 °C after 8 days of incubation with a biosurfactant concentration of 0.99 mg/mL. This work supports the possible application of biosurfactants extracted from corn steep water as preservatives and antimicrobial agents against fungal contaminations on agrifood products., Ministerio de Economía y Competitividad | Ref. RTI2018-093610-B-100, Ministerio de Economía y Competitividad | Ref. IJCI-2016-27445, Ministerio de Educación, Cultura y Deporte | Ref. FPU15/00205, Universidade de Vigo
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Influence of micelle formation on the adsorption capacity of a biosurfactant extracted from corn on dyed hair

  • Rincón Fontán, Mirian
  • Rodríguez López, Lorena
  • Vecino Bello, Xanel
  • Cruz Freire, José Manuel
  • Moldes Menduiña, Ana Belén
Human hair contains fatty acids (palmitic, palmitoleic, oleic and stearic acid) that prevent hair dryness and avoid lower hair density of the scalp that can be caused when hair is dyed. These acids are also present in the composition of the amphoteric biosurfactant obtained from corn steep liquor, an agro-industrial stream generated by the corn wet-milling industry. This biosurfactant has a molecular weight of 1542 Da, with a similar mass spectrum to that of Fengycin, a biosurfactant produced by Bacillus subtilis strains. Few studies exist in the literature on the interaction of hair and biosurfactants, nor are there studies on the influence of micelle formation on biosurfactant adsorption capacity. Moreover, this is supposedly the first work in which a biosurfactant is applied to dyed hair. Different concentrations of biosurfactant were applied to dyed hair between 20–50 °C during 2–30 min of treatment. Theoretical models were obtained, which allowed the prediction of the amount of biosurfactant that can be entrapped by dyed hair. A maximum capacity of 10 549 μg g−1 was achieved at 295 mg L−1 of biosurfactant, thus it could be observed that dyed hair mainly adsorbed the biosurfactant above its critical micellar concentration, at which point the biosurfactant is in micellar form. Furthermore, this treatment maintains the dyed hair structure in a good state., Ministerio de Economía y Competitividad | Ref. CTM2015-68904, Ministerio de Economía y Competitividad | Ref. FJCI-2014-19732, Ministerio de Educación, Cultura y Deporte | Ref. FPU15/00205
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chemoselective hydrogenation of cinnamaldehyde: A comparison of the immobilization of Ru-phosphine complex on graphite oxide and on graphitic surfaces

  • Dongil, Ana Belén
  • Bachiller-Baeza, B.
  • Guerrero-Ruiz, Antonio
  • Rodríguez-Ramos, Inmaculada
The homogeneous complex Ru(PPh3)3Cl2 has been immobilized onto three different carbon materials: graphite, carbon nanofibers, and graphite oxide (GO). All the supports were previously functionalized with (bis(2-aminoethyl)amine). For graphite oxide, a second functionalization strategy using N-[3-(tri-methoxysilyl)propyl]-etylenediamine (TPEN) was also followed. XRD, NMR, TG, TPD, DRIFTS, and XPS techniques were applied for the characterization of the functionalized supports and the hybrid catalysts. The hybrid catalysts have been tested in the hydrogenation of cinnamaldehyde and, although less active, they showed selectivities comparables to that for the homogeneous complex. The different behavior observed for the samples after recycling and reusing can be related to the ligand-support interaction type. While activity and selectivity are preserved for the Ru grafted on the covalent-functionalized GO-TPEN, variations in activity and selectivity are observed for the amine-functionalized samples. © 2011 Elsevier Inc. All rights reserved., Authors acknowledge the MICINN of Spain (Projects CTQ-2008-06839-C03-01 and -03 and EUI2008-00185 and -00205) for financial support., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

  • Morancho Armisen, Beatriz
  • Román Alonso, Macarena
  • Ovejero Romero, Pablo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
  • Rius Ruiz, Irene
  • Escorihuela Baez, Marta
Cancer; Antigen; Resistance, Cáncer; Antígeno; Resistencia, Càncer; Antigen; Resistència, Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA+/HER2+ MKN45 cells and TCBs directed against CEA or HER2, we show that the mechanism of resistance to a TCB is dependent on the tumor antigen. Acquired resistant models to a high-affinity-CEA-targeted TCB exhibit a reduction of CEA levels due to transcriptional silencing, which is reversible upon 5-AZA treatment. In contrast, a HER2-TCB resistant model maintains HER2 levels and exhibit a disruption of the interferon-gamma signaling. These results will help in the design of combinatorial strategies to increase the efficacy of cancer immunotherapies and to anticipate and overcome resistances., This work was supported by Asociación Española Contra el Cancer (AECC), Breast Cancer Research Foundation (BCRF-21-008), and Instituto de Salud Carlos III (PI19/01181). A.M.S. was funded by the Spanish Government (PFIS FI20/00188). B.M. was funded by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). M.R.A. was funded by Agency for Management of University and Research Grants (AGAUR, 2022 FI_B2 00080). P.O.R. was funded by the BBVA. E.J.A. was funded by the AECC (POSTD211413AREN). VHIO acknowledges the Cellex Foundation for providing research facilities and equipment, the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from the Institute of Health Carlos III (ISCIII), and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 SLT008/18/00205) for their support on this research. The authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S/AEI/10.13039/501100011033) and for the Cancer Immunology and Immunotherapy (CAIMI-2) program funded by BBVA Foundation. We would like to remark the funding from B.M PERIS (Spain). The authors thank Dr. Anne Freimoser-Grundschober and Roche for helping provide the TCBs. The graphical abstract was created with BioRender.com.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Brunet Mauri, Maria Salut
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Cordeiro, Anna
  • Gallardo, David|||0000-0003-1615-4592
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Tormo, Mar|||0000-0001-9622-1649
  • Heras, Inmaculada
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Duarte, Rafael|||0000-0002-5240-9815
  • Llano Queipo, María Paz de
  • Bargay, Joan|||0000-0002-6739-3916
  • Sampol, Antonia|||0000-0001-7465-6203
  • Nomdedeu, Meritxell
  • Risueño, Ruth M.|||0000-0003-4048-9536
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Sierra, Jorge|||0000-0002-7966-0356
  • Monzo, Mariano|||0000-0003-2322-4851
  • Navarro, Alfons|||0000-0001-6071-0926
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although their role in acute myeloid leukemia (AML) is mostly unknown.We have examined the expression of the lncRNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) in 241 AML patients. We have correlated HOTAIRM1 expression with a miRNA expression profile. We have also analyzed the prognostic value of HOTAIRM1 expression in 215 intermediate-risk AML (IR-AML) patients.The lowest expression level was observed in acute promyelocytic leukemia (P < 0.001) and the highest in t(6;9) AML (P = 0.005). In 215 IR-AML patients, high HOTAIRM1 expression was independently associated with shorter overall survival (OR:2.04;P = 0.001), shorter leukemia-free survival (OR:2.56; P < 0.001) and a higher cumulative incidence of relapse (OR:1.67; P = 0.046). Moreover, HOTAIRM1 maintained its independent prognostic value within the favorable molecular subgroup (OR: 3.43; P = 0.009). Interestingly, HOTAIRM1 was overexpressed in NPM1-mutated AML (P < 0.001) and within this group retained its prognostic value (OR: 2.21; P = 0.01). Moreover, HOTAIRM1 expression was associated with a specific 33-microRNA signature that included miR-196b (P < 0.001). miR-196b is located in the HOX genomic region and has previously been reported to have an independent prognostic value in AML. miR-196b and HOTAIRM1 in combination as a prognostic factor can classify patients as high-, intermediate-, or low-risk (5-year OS: 24% vs 42% vs 70%; P = 0.004).Determination of HOTAIRM1 level at diagnosis provided relevant prognostic information in IR-AML and allowed refinement of risk stratification based on common molecular markers. The prognostic information provided by HOTAIRM1 was strengthened when combined with miR-196b expression. Furthermore, HOTAIRM1 correlated with a 33-miRNA signature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

  • Álvarez Larrán, Alberto|||0000-0001-6387-4619
  • Garrote, Marta
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
  • Pérez-Encinas, Manuel|||0000-0001-9943-4404
  • Mata-Vazquez, M.Isabel
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Arellano-Rodrigo, Eduardo|||0000-0001-6236-7826
  • Gómez, Montse
  • García, Regina
  • García Gutiérrez, Valentín|||0000-0003-4752-0815
  • Gasior Kabat, Mercedes
  • Cuevas, Beatriz|||0000-0001-7555-3361
  • Angona, Anna|||0000-0002-0965-9501
  • Gómez-Casares, María Teresa
  • Martínez, Clara
  • Magro, Elena
  • Ayala, Rosa|||0000-0002-2699-8353
  • Del Orbe Barreto, Rafael Andrés|||0000-0002-1240-1958
  • Pérez-López, Raúl
  • Fox, Maria Laura|||0000-0002-0062-6607
  • Raya, José-Maria
  • Guerrero, Lucía
  • García-Hernández, Carmen
  • Caballero, Gonzalo
  • Murillo, Ilda
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Ramírez, M.José
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Pereira, Aarturo
Background: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. Methods: A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. To minimize biases in treatment allocation, all results were adjusted by a propensity score for receiving ruxolitinib or BAT. Results: Patients receiving ruxolitinib had a significantly lower rate of arterial thrombosis than those on BAT (0.4% vs 2.3% per year; P =.03), and this persisted as a trend after adjustment for the propensity to have received the drug (incidence rate ratio, 0.18; 95% confidence interval, 0.02-1.3; P =.09). There were no significant differences in the rates of venous thrombosis (0.8% and 1.1% for ruxolitinib and BAT, respectively; P =.7) and major bleeding (0.8% and 0.9%, respectively; P =.9). Ruxolitinib exposure was not associated with a higher rate of second primary cancers, including all types of neoplasia, noncutaneous cancers, and nonmelanoma skin cancers. After a median follow-up of 3.5 years, there were no differences in survival or progression to acute leukemia or myelofibrosis between the 2 groups. Conclusions: The results suggest that ruxolitinib treatment for PV patients with resistance/intolerance to hydroxyurea may reduce the incidence of arterial thrombosis. Lay Summary: Ruxolitinib is better than other available therapies in achieving hematocrit control and symptom relief in patients with polycythemia vera who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides an additional benefit in preventing thrombosis or disease progression. We retrospectively studied the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to whether they subsequently received ruxolitinib (n = 105) or the best available therapy (n = 272). Our findings suggest that ruxolitinib could reduce the incidence of arterial thrombosis, but a disease-modifying effect could not be demonstrated for ruxolitinib in this patient population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Manero-Rupérez, Noemí
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Soler Castany, Marta
  • Ros-Blanco, Lia
  • Navarro, Pilar|||0000-0003-4314-4584
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). LDL aggregation can be efficiently inhibited by low-density lipoprotein receptor-related protein 1 (LRP1)-based peptides. The objectives of this work were: (i) to determine if aggregated LDLs affect the intracellular cholesteryl ester (CE)/free cholesterol (FC) ratio and/or the tumor pancreatic cell proliferation, using sphingomyelinase-modified LDL particles (Aggregated LDL, AgLDL); and (ii) to test whether LRP1-based peptides, highly efficient against LDL aggregation, can interfere in these processes. For this, we exposed human pancreatic cancer cell lines (PANC-1, RWP-1 and Capan-1) to native (nLDL) or AgLDLs in the absence or presence of LRP1-based peptides (DP3) or irrelevant peptides (IP321). Results of thin-layer chromatography (TLC) following lipid extraction indicate that AgLDLs induce a higher intracellular CE/FC ratio than nLDL, and that DP3 but not IP321 counteracts this effect. AgLDLs also increase PANC-1 cell proliferation, which is inhibited by the DP3 peptide. Our results indicate that AgLDL-induced intracellular CE accumulation plays a crucial role in the proliferation of pancreatic tumor cell lines. Peptides with anti-LDL aggregation properties may thus exhibit anti-tumor effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms modulating foam cell formation in the arterial intima, exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martinez, A.
  • Claudi, Lene
  • Garcia, E.
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Polishchuk, A.
  • Piñero, Janet|||0000-0003-1244-7654
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Sanz, F.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

  • Morancho Armisen, Beatriz
  • Román Alonso, Macarena
  • Ovejero Romero, Pablo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
  • Rius Ruiz, Irene
  • Escorihuela Baez, Marta
Cancer; Antigen; Resistance, Cáncer; Antígeno; Resistencia, Càncer; Antigen; Resistència, Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA+/HER2+ MKN45 cells and TCBs directed against CEA or HER2, we show that the mechanism of resistance to a TCB is dependent on the tumor antigen. Acquired resistant models to a high-affinity-CEA-targeted TCB exhibit a reduction of CEA levels due to transcriptional silencing, which is reversible upon 5-AZA treatment. In contrast, a HER2-TCB resistant model maintains HER2 levels and exhibit a disruption of the interferon-gamma signaling. These results will help in the design of combinatorial strategies to increase the efficacy of cancer immunotherapies and to anticipate and overcome resistances., This work was supported by Asociación Española Contra el Cancer (AECC), Breast Cancer Research Foundation (BCRF-21-008), and Instituto de Salud Carlos III (PI19/01181). A.M.S. was funded by the Spanish Government (PFIS FI20/00188). B.M. was funded by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). M.R.A. was funded by Agency for Management of University and Research Grants (AGAUR, 2022 FI_B2 00080). P.O.R. was funded by the BBVA. E.J.A. was funded by the AECC (POSTD211413AREN). VHIO acknowledges the Cellex Foundation for providing research facilities and equipment, the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from the Institute of Health Carlos III (ISCIII), and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 SLT008/18/00205) for their support on this research. The authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S/AEI/10.13039/501100011033) and for the Cancer Immunology and Immunotherapy (CAIMI-2) program funded by BBVA Foundation. We would like to remark the funding from B.M PERIS (Spain). The authors thank Dr. Anne Freimoser-Grundschober and Roche for helping provide the TCBs. The graphical abstract was created with BioRender.com.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).